open access
Molecular classification of endometrial carcinoma, is it the new era of precision medicine?
Affiliations- Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Poland
- 2nd Chair and Department Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland
- Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Poland
open access
Abstract
For many years endometrial cancer has been subdivided into oestrogen — dependent (type I) and oestrogen — independent (type II), according to classical Bokhman classification. Histopathological evaluation including type and grade of tumour, along with clinical factors have been considered as very important prognostic factors that impact treatment decision. However, histologically similar tumours may have different outcomes. Recent molecular findings and new histopathological parameters have given new concept on risk stratification. The Cancer Genome Atlas Research Network (TCGA) of tumours have brought new insights into endometrial cancer management. Four molecular subgroups have been described: POLE ultramutated (POLE mut), p53 mutant (p53abn), mismatch repair deficient (MMRd) and non-specific molecular profile (NSMP). This new subdivision has been recently introduced in the European risk stratification system.
Abstract
For many years endometrial cancer has been subdivided into oestrogen — dependent (type I) and oestrogen — independent (type II), according to classical Bokhman classification. Histopathological evaluation including type and grade of tumour, along with clinical factors have been considered as very important prognostic factors that impact treatment decision. However, histologically similar tumours may have different outcomes. Recent molecular findings and new histopathological parameters have given new concept on risk stratification. The Cancer Genome Atlas Research Network (TCGA) of tumours have brought new insights into endometrial cancer management. Four molecular subgroups have been described: POLE ultramutated (POLE mut), p53 mutant (p53abn), mismatch repair deficient (MMRd) and non-specific molecular profile (NSMP). This new subdivision has been recently introduced in the European risk stratification system.
Keywords
molecular classif endometrial cancer; POLE mutations; p53 mutations; MMRd; NSMP
About this articleTitle
Molecular classification of endometrial carcinoma, is it the new era of precision medicine?
Journal
Issue
Article type
Review paper
Pages
163-167
Published online
2021-12-28
Page views
6212
Article views/downloads
1636
DOI
Pubmed
Bibliographic record
Ginekol Pol 2022;93(2):163-167.
Keywords
molecular classif endometrial cancer
POLE mutations
p53 mutations
MMRd
NSMP
Authors
Mariusz Bidzinski
Anna Danska-Bidzinska
Agnieszka Rychlik
Jolanta Kypryjanczyk
Michal Pyzlak
Szymon Piatek
References (30)- WHO, International Agency for Research on Cancer. Corpus uteri. https://gco.iarc.fr/today/data/factsheets/cancers/24-Corpus-uteri-fact-sheet.pdf (2021-03-01).
- Siegel R, Miller K, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30.
- Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(1): 16–41.
- NCCN — Evidence-Based Cancer Guidelines, Oncology Drug Compendium, Oncology Continuing Medical Education. https://www.nccn.org/ (2021-03-01).
- Kurman RJ, Carcangiu ML, Herrington S. et al.. WHO classification of tumours of female reproductive organs. 4th ed. WHO Press, Lyon 2014.
- Levine DA. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73.
- Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2): 299–310.
- Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016; 22(16): 4215–4224.
- Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5): 802–813.
- Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst. 2015; 107(1): 402.
- Vermij L, Smit V, Nout R, et al. Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2020; 76(1): 52–63.
- van Gool IC, Eggink FA, Freeman-Mills L, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res. 2015; 21(14): 3347–3355.
- Van Gool IC, Rayner E, Osse EM, et al. Adjuvant treatment for proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues. Clin Cancer Res. 2018; 24(13): 3197–3203.
- Creutzberg CL, Leon-Castillo A, Boer SMde, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. Ann Oncol. 2019; 30(Suppl 5): v899–v900.
- Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018; 29(5): 1180–1188.
- McMeekin DS, Tritchler DL, Cohn DE, et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology/gynecologic oncology group study. J Clin Oncol. 2016; 34(25): 3062–3068.
- Wortman BG, Creutzberg CL, Putter H, et al. PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9): 1067–1074.
- Kommoss FKf, Karnezis AN, Kommoss F, et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018; 119(4): 480–486.
- Gezer Ş, Bayrak BY. Metastatic and synchronous ovarian involvement in low-risk endometrial cancer; clinicopathological analysis with detection of DNA mismatch repair deficiency. Ginekol Pol. 2021 [Epub ahead of print].
- Paulino E, de Melo AC. Adjuvant treatment of endometrial cancer in molecular era: Are we ready to move on? Crit Rev Oncol Hematol. 2020; 153: 103016.
- Wortman BG, Creutzberg CL, Putter H, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9): 1067–1074.
- Budak E, Kahraman DS, Budak A, et al. The prognostic significance of serum CA125 levels with ER, PR, P53 and Ki-67 expression in endometrial carcinomas. Ginekol Pol. 2019; 90(12): 675–683.
- Buza N, English DP, Santin AD, et al. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol. 2013; 26(12): 1605–1612.
- de Jonge MM, Auguste A, van Wijk LM, et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin Cancer Res. 2019; 25(3): 1087–1097.
- Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015; 1(9): 1319–1323.
- Azad NS, Gray RJ, Overman MJ, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol. 2020; 38(3): 214–222.
- Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019; 154(2): 314–322.
- Fader A, Roque D, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018; 36(20): 2044–2051.
- Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014; 138(3): 343–350.
- Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
